Protein-structure-guided discovery of functional mutations across 19 cancer types.

Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. Cell Rep (2016) 0.77

3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome Med (2017) 0.77

Molecular modeling and molecular dynamic simulation of the effects of variants in the TGFBR2 kinase domain as a paradigm for interpretation of variants obtained by next generation sequencing. PLoS One (2017) 0.75

A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors. Sci Rep (2016) 0.75

Insights into cancer severity from biomolecular interaction mechanisms. Sci Rep (2016) 0.75

Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types. Sci Rep (2017) 0.75

Comparison of algorithms for the detection of cancer drivers at subgene resolution. Nat Methods (2017) 0.75

The Protein Data Bank. Nucleic Acids Res (2000) 187.10

Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res (2005) 44.08

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93

Cancer genome landscapes. Science (2013) 25.33

SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics (2006) 21.54

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16

Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res (2011) 18.50

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA (2006) 11.22

Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99

The Protein Data Bank: a historical perspective. Acta Crystallogr A (2007) 10.25

DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res (2013) 6.73

MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73

Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol (2008) 3.85

Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18

Functional impact bias reveals cancer drivers. Nucleic Acids Res (2012) 2.96

Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J (2006) 2.67

Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther (2010) 2.33

IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods (2013) 2.10

OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics (2013) 1.90

LS-SNP/PDB: annotated non-synonymous SNPs mapped to Protein Data Bank structures. Bioinformatics (2009) 1.61

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res (2009) 1.54

SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res (2012) 1.39

Heparin-binding growth factor 1 stimulates tyrosine phosphorylation in NIH 3T3 cells. Mol Cell Biol (1989) 1.29

Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06

Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother (2012) 1.05

MutDB: update on development of tools for the biochemical analysis of genetic variation. Nucleic Acids Res (2007) 1.03

Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions. Nucleic Acids Res (2014) 1.01

(n-3) fatty acids and cancer therapy. J Nutr (2004) 1.00

MuPIT interactive: webserver for mapping variant positions to annotated, interactive 3D structures. Hum Genet (2013) 0.99

Four distances between pairs of amino acids provide a precise description of their interaction. PLoS Comput Biol (2009) 0.86

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. PLoS One (2013) 0.85

Oncogenic MAP2K1 mutations in human epithelial tumors. Carcinogenesis (2012) 0.85

Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). PLoS One (2013) 0.82

Interpreting protein networks with three-dimensional structures. Nat Methods (2013) 0.79

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun (2017) 1.42

The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet (2016) 0.89

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet (2016) 0.84

novoBreak: local assembly for breakpoint detection in cancer genomes. Nat Methods (2016) 0.79